The Sensex is expected to open lower on Tuesday after hitting record high in the previous session as Asian markets remained tepid in the early trade. At 7:50 am, SGX Nifty was trading at 11,091.50, down 7.50 points or 0.07 per cent.

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

In Asia, Japan's Nikkei bounced 0.4 per cent as a pullback in the yen eased concerns about earnings pressure on exporters. Moves elsewhere were marginal with MSCI’s broadest index of Asia-Pacific shares outside Japan barely changed. 

On Wall Street, a rally in tech stocks made up for an otherwise dull day on Wall Street where the Dow eased 0.06 per cent, while the S&P 500 gained 0.18 per cent and the Nasdaq 0.28 per cent.

Here are top five stocks that will remain in focus today:

Idea Cellular: Vodafone India and Idea Cellular and are likely to pay up the Rs 7,268 crore in dues towards spectrum charges demanded by the government to get final nod from the Department of Telecommunications (DoT) as any recourse to litigation would mean potential delay in the $23 bn merger.

InterGlobe Aviation: IndiGo revised its 2017 data. The airline told the Directorate General of Civil Aviation (DGCA) in July that these now stand at 14,628, up from the 340 it had filed previously. The airline said this was because the regulator had asked it to be stricter in reporting glitches, according to an ET report.

ACC: Cement major ACC reported marginal increase in consolidated net profit to Rs 329 crore for the June quarter. It had posted Rs 326 crore profit in April-June period of last fiscal, ACC Ltd said in a BSE filing. The company, which follows January-December as its financial year, said net sales were at Rs 3,768 crore, up from Rs 3,329 crore in the year-ago period.

WATCH ZEE BUSINESS VIDEO HERE

Punjab National Bank, Allahabad Bank: According to reports, PNB has received Rs 2,816 crore capital infusion from the government, while Allahabad Bank has received Rs 1,790 crore.

Syngene: Syngene International, a leading global Contract Research Organization, announced the expansion of the scope of its R&D collaboration with Baxter Healthcare Corporation, a global healthcare company. As part of the expansion, Syngene will set up additional infrastructure at the dedicated Baxter Global Research Center (BGRC) as well as increase the size of its scientific team working on Baxter projects. The duration of the agreement has also been extended until 2024.